VJHemOnc is committed to improving our service to you

SOHO 2020 | Magrolimab in TP53 mutated AML and MDS

VJHemOnc is committed to improving our service to you

David Sallman

David Sallman, MD, of H. Lee Moffitt Cancer Center, Tampa, FL, outlines the use of magrolimab in TP53 mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in combination with azacitidine. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter